Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Organon |
---|---|
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00651807 |
This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on:
Condition | Intervention | Phase |
---|---|---|
Benign Prostatic Hyperplasia (BPH) |
Drug: etonogestrel Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH) |
Enrollment: | 16 |
Study Start Date: | March 2008 |
Study Completion Date: | August 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Active Comparator
etonogestrel
|
Drug: etonogestrel
Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
|
Arm 2: Placebo Comparator
Placebo
|
Drug: Placebo
Every day one tablet up to 8 weeks
|
Ages Eligible for Study: | 50 Years to 80 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | NV Organon, a part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 304001 |
Study First Received: | March 31, 2008 |
Last Updated: | August 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00651807 History of Changes |
Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Germany: Federal Institute for Drugs and Medical Devices; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Hypertrophy Hyperplasia Desogestrel Prostatic Diseases Prostatic Hyperplasia |
Contraceptive Agents Contraceptive Agents, Female 3-keto-desogestrel Genital Diseases, Male |
Hyperplasia Pathologic Processes Prostatic Diseases Prostatic Hyperplasia Contraceptive Agents Therapeutic Uses |
Physiological Effects of Drugs Contraceptive Agents, Female Reproductive Control Agents 3-keto-desogestrel Genital Diseases, Male Pharmacologic Actions |